roaccutane 20 mg pehmekapsel
roche eesti osaühing - isotretinoiin - pehmekapsel - 20mg 30tk; 20mg 100tk; 20mg 50tk; 20mg 20tk
roferon-a süstelahus
roche eesti osaühing - alfa-2a-interferoon - süstelahus - 9000000rÜ 0.5ml 12tk; 9000000rÜ 0.5ml 1tk; 9000000rÜ 0.5ml 6tk; 9000000rÜ 0.5ml 5tk
roaccutane 10 mg pehmekapsel
roche eesti osaühing - isotretinoiin - pehmekapsel - 10mg 50tk; 10mg 100tk; 10mg 30tk
roferon-a süstelahus
roche eesti osaühing - alfa-2a-interferoon - süstelahus - 3000000rÜ 0.5ml 12tk; 3000000rÜ 0.5ml 5tk
valcyte suukaudse lahuse pulber
roche eesti osaühing - valgantsikloviir - suukaudse lahuse pulber - 50mg 1ml 100ml 1tk
dormicum süste-/infusioonilahus
roche eesti osaühing - midasolaam - süste-/infusioonilahus - 5mg 1ml 3ml 3tk; 5mg 1ml 1ml 10tk
cymevene infusioonilahuse kontsentraadi pulber
roche eesti osaühing - gantsikloviir - infusioonilahuse kontsentraadi pulber - 500mg 5tk
polivy
roche registration gmbh - polatuzumab vedotin - lümfoom, b-raku - antineoplastilised ained - polivy koos bendamustine ja rituksimabi on näidustatud ravi täiskasvanud patsientidel, kellel on taastekkinud/tulekindlad hajus suur b-rakulise lümfoomi (dlbcl), kes ei ole kandidaadid vereloome tüvirakkude siirdamist. polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (r-chp) is indicated for the treatment of adult patients with previously untreated diffuse large b-cell lymphoma (dlbcl).
rozlytrek
roche registration gmbh - entrectinib - cancer; carcinoma, non-small-cell lung - antineoplastilised ained - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.
xofluza
roche registration gmbh - baloxavir marboxil - gripp, inimene - viirusevastased ravimid süsteemseks kasutamiseks - treatment of influenzaxofluza is indicated for the treatment of uncomplicated influenza in patients aged 1 year and above. post exposure prophylaxis of influenzaxofluza is indicated for post-exposure prophylaxis of influenza in individuals aged 1 year and above. xofluza should be used in accordance with official recommendations.